{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:02:43Z","timestamp":1788904963358,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T00:00:00Z","timestamp":1528329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jpeds.2018.05.042","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T01:48:04Z","timestamp":1532483284000},"page":"166-175.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease"],"prefix":"10.1016","volume":"201","author":[{"given":"Gerd","family":"Horneff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke M.B.","family":"Seyger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Arikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Kalabic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn K.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Tarzynski-Potempa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Hyams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2018.05.042_bib0010","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s10067-014-2498-1","article-title":"Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years","volume":"33","author":"Kingsbury","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0015","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10067-012-2082-5","article-title":"Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan","volume":"31","author":"Imagawa","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0020","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0025","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/acr.22657","article-title":"A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis","volume":"67","author":"Burgos-Vargas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0040","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MIB.0000000000001021","article-title":"Long-term efficacy and safety of adalimumab in pediatric patients with Crohn's disease","volume":"23","author":"Faubion","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0045","series-title":"Humira (adalimumab). Full prescribing information","year":"2016"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0050","series-title":"Humira (adalimumab). Summary of product characteristics","year":"2016"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0055","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0060","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/14740338.2015.1042453","article-title":"Safety of biologic therapies for the treatment of juvenile idiopathic arthritis","volume":"14","author":"Horneff","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0065","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.38741","article-title":"Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry","volume":"66","author":"Schmeling","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0070","article-title":"Safety and effectiveness of adalimumab \u00b1 methotrexate for the treatment of polyarticular juvenile idiopathic arthritis [abstract]","volume":"68","author":"Lovell","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0075","first-page":"121","article-title":"Inflammatory bowel disease in pediatric patients: characteristics of newly diagnosed patients from the CEDATA-GPGE Registry","volume":"112","author":"Buderus","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0080","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jamadermatol.2017.3029","article-title":"Safety of systemic agents for the treatment of pediatric psoriasis","volume":"153","author":"Bronckers","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0085","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0090","author":"National Center for Health Statistics"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0095","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/MIB.0000000000001075","article-title":"Growth improvement with adalimumab treatment in children with moderately to severely active Crohn's disease","volume":"23","author":"Walters","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"suppl 10","key":"10.1016\/j.jpeds.2018.05.042_bib0100","article-title":"The impact of adalimumab on growth in patients with juvenile idiopathic arthritis [abstract]","volume":"64","author":"Lovell","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0105","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/ajg.2015.284","article-title":"Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a Nationwide Danish Cohort Study 1977-2013","volume":"110","author":"Kantso","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0110","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1159\/000233297","article-title":"Therapy- and non\u2013therapy-dependent infectious complications in inflammatory bowel disease","volume":"27","author":"Epple","year":"2009","journal-title":"Dig Dis"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ncpgasthep1004","article-title":"Infections and IBD","volume":"5","author":"Irving","year":"2008","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0120","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.3748\/wjg.v20.i43.16014","article-title":"Risk of infections associated with biological treatment in inflammatory bowel disease","volume":"20","author":"Andersen","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0130","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/ar4452","article-title":"Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study","volume":"16","author":"Burmester","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0135","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ibd.20956","article-title":"Adalimumab safety in global clinical trials of patients with Crohn's disease","volume":"15","author":"Colombel","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"suppl 10","key":"10.1016\/j.jpeds.2018.05.042_bib0140","article-title":"Efficacy and safety of adalimumab in adult patients with polyarticular juvenile idiopathic arthritis [abstract]","volume":"67","author":"Lovell","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2296-7-23","article-title":"Serious infections in children: an incidence study in family practice","volume":"7","author":"Van den Bruel","year":"2006","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0150","first-page":"538","article-title":"Signs and symptoms for diagnosis of serious infections in children: a prospective study in primary care","volume":"57","author":"Van den Bruel","year":"2007","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0155","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.cgh.2014.01.021","article-title":"Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review","volume":"12","author":"Dulai","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0160","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","article-title":"Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis","volume":"60","author":"Giannini","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0165","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0170","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0175","series-title":"Enbrel (etanercept). Summary of product characteristics","year":"2015"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0180","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.21885","article-title":"Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis","volume":"54","author":"Lovell","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0185","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0190","series-title":"Remicade (infliximab). Full prescribing information","year":"2015"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0195","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0200","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1185\/03007995.2010.547575","article-title":"Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension","volume":"27","author":"Hyams","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"suppl 10","key":"10.1016\/j.jpeds.2018.05.042_bib0205","article-title":"Uveitis associated to polyarticular juvenile idiopathic arthritis [abstract]","volume":"68","author":"Foeldvari","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0210","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2018.05.042_bib0215","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/annrheumdis-2014-eular.1559","article-title":"Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab","volume":"73","author":"Minden","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347618307558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347618307558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:32:20Z","timestamp":1755235940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347618307558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":42,"alternative-id":["S0022347618307558"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2018.05.042","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2018.05.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2018.07.106","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}